Abstract
Bone marrow cells expressing the surface antigen CD34 comprise approximately 1% of harvested marrow and are highly enriched for marrow progenitor cells, including the cells believed to be responsible for long-term engraftment following bone marrow transplantation (BMT). Selection of CD34-expressing cells was applied in allogeneic BMT (alloBMT) to decrease the number of T lymphocytes in the infused marrow in an attempt to prevent severe graft-versus-host disease (GVHD). We report 14 patients who underwent HLA-identical sibling-matched alloBMT with marrow-enriched for CD34 cells using the Isolex 300 SA device. Patients received total body irradiation, thiotepa, cyclophosphamide, antithymocyte globulin and methylprednisolone prior to marrow infusion. No post-transplantation immunosuppressive therapy was given except for a 5-week course of steroids. The purity of the infused marrow was 64.9 ± 6.0% (mean ± s.e.m.) CD34-positive cells and patients received a mean of 1.24 ± 0.21 × 106 CD34 cells/kg. A mean of 9.4 ± 1.7 × 104 CD3 T cells/kg were present in the CD34-enriched product, representing a 2.7 ± 0.1 log depletion. There were no graft rejections and patients achieved a sustained absolute granulocyte count of >500 in a median of 10.5 days and a sustained platelet engraftment of >20000 untransfused in a median of 27 days. Patients were discharged a median of 21.5 days after marrow infusion. There were no instances of grade III or IV graft-versus-host disease (GVHD) and no unexpected adverse events during the transplant hospitalization. With a median follow-up of 12 months, the estimated 100 day survival is 86 ± 9%. CD34 selection in alloBMT permits rapid engraftment without unanticipated toxicities.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cornetta, K., Gharpure, V., Mills, B. et al. Rapid engraftment after allogeneic transplantation using CD34-enriched marrow cells. Bone Marrow Transplant 21, 65–71 (1998). https://doi.org/10.1038/sj.bmt.1701048
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1701048
Keywords
This article is cited by
-
Effect of dendritic cell-cytokine-induced killer cells in patients with advanced colorectal cancer combined with first-line treatment
World Journal of Surgical Oncology (2017)
-
Oral busulfan pharmacokinetics and engraftment in children with Hurler syndrome and other inherited metabolic storage diseases undergoing hematopoietic cell transplantation
Bone Marrow Transplantation (2001)
-
Excessive T cell depletion of peripheral blood stem cells has an adverse effect upon outcome following allogeneic stem cell transplantation
Bone Marrow Transplantation (2001)
-
Large-scale mobilization and isolation of CD34+ cells from normal donors
Bone Marrow Transplantation (2000)